Schering Corporation

Dendreon Corporation

Other

Jinping L McCormick

Ashit K Ganguly

Anil K Saksena

Viyyoor Moopil Girijavallabhan

Frank W Bennett

Raymond G Lovey

F George Njoroge

Stephane L Bogen

Ashok Arasappan

Yi-Tsung Liu

Odile Esther Levy

Patrick A Pinto

Russell E Pike

Marguerita S Lim-Wilby

Edwin Jao

Haiyan Wang

Tejal Parekh

Scott Jeffrey Kemp

Zhaoning Zhu

Srikanth Venkatraman

Kevin X Chen

Tin-Yau Chan

Bama Santhanam

Susan Y Tamura

Terence Kevin Brunck

Yuhua Huang

Henry A Vaccaro

Henry M Vaccaro

Wanli Wu

Siska Hendrata

Tze-Ming Chan

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Peptides as NS3-serine protease inhibitors of hepatitis C virus

The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Ribavirin derivatives represented by the formula V, pharmaceutical compositions containing them as well as the use of the ribavirin derivatives represented by the formula V for the preparation of a medicament for the treatment of susceptible viral infections, for example, chronic hepatitis C infections administrating, the ribavirin derivatives being represented by formula V are disclosed.

Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection

The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such peptides as well as methods of using them to treat disorders associated with the HCV protease.

A method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin derivative of formula I and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks.

5&prime;-Amino acid esters of ribavirin represented by formula I:

5&prime;-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon

Novel oligosaccharide antibiotics of formula I and I' are disclosed, together with a method for their preparation.

Oligosaccharide antibiotics and process for preparation thereof

Growing community of inventors

Edison, NJ, United States of America

Jinping L McCormick